留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

勃起功能障碍药物治疗的研究现状

龚知城,  左翼,  钟义洋,  赵善超

downloadPDF
文章导航 > 分子影像学杂志  > 2018 >  41(2): 201-206
龚知城, 左翼, 钟义洋, 赵善超. 勃起功能障碍药物治疗的研究现状[J]. 分子影像学杂志, 2018, 41(2): 201-206. doi: 10.3969/j.issn.1674-4500.2018.02.16
引用本文: 龚知城, 左翼, 钟义洋, 赵善超. 勃起功能障碍药物治疗的研究现状[J]. 分子影像学杂志, 2018, 41(2): 201-206. doi: 10.3969/j.issn.1674-4500.2018.02.16
shu
Zhicheng GONG, Yi ZUO, Yiyang ZHONG, Shanchao ZHAO. Research status of erectile dysfunction pharmacotherapy[J]. Journal of Molecular Imaging, 2018, 41(2): 201-206. doi: 10.3969/j.issn.1674-4500.2018.02.16
Citation: Zhicheng GONG, Yi ZUO, Yiyang ZHONG, Shanchao ZHAO. Research status of erectile dysfunction pharmacotherapy[J]. Journal of Molecular Imaging, 2018, 41(2): 201-206. doi: 10.3969/j.issn.1674-4500.2018.02.16
shu

勃起功能障碍药物治疗的研究现状

doi: 10.3969/j.issn.1674-4500.2018.02.16
  • 1.

    南方医科大学南方医院泌尿外科，广东  广州  510515

  • 2.

    广州番禺第六人民医院泌尿外科，广东 广州 511422

详细信息
    作者简介:

    龚知城，博士，E-mail: 916351599@qq.com；左 翼，副主任护师，E-mail: 916351599@qq.com;龚知城，左翼为共同第一作者

    通讯作者:

    赵善超，主任医师，教授，博士生导师，E-mail: zhaoshanchao@263.net

Research status of erectile dysfunction pharmacotherapy

  • 1.

    Department of Urology, Nanfang Hospital/The First School of Clinical Medicine of Southern Medical University, Guangzhou 510515, China

  • 2.

    Department of Urology, The Sixth People's Hospital of Guangzhou Panyu,Guangzhou 511422,China

    摘要
  • 摘要: 虽然口服磷酸二酯酶-5抑制剂、雄激素治疗是目前治疗勃起功能障碍的常见治疗方式，但是由于勃起功能障碍具有多种致病机制，部分患者对这些药物反应不佳。许多研究人员试图寻找新的治疗策略。靶向药物治疗针对中枢和外周途径。中枢作用的包括黑皮质素受体激动剂、多巴胺能激动剂、克拉维酸（紫杉醇）。外周作用的包括可溶性鸟苷酸环化酶活化剂和Rho激酶抑制剂。蛋白质疗法和基因疗法通过恢复或再生海绵体血管内皮细胞、海绵体神经或抑制继发于神经血管功能障碍的组织纤维化，使受损的阴茎勃起组织再生。文章回顾磷酸二酯酶-5抑制剂治疗、雄激素治疗，介绍临床或临床前研究中勃起功能障碍的药物治疗策略，其研究结果为将来的临床应用打下了坚实的基础。

     

    Abstract: Although oral phosphodiesterase-5 (PDE5) inhibitors and androgen therapy are common treatments for erectile dysfunction (ED), some patients respond poorly to these drugs because of ED’s multiple pathogenic mechanisms. Many researchers have tried to find new treatment strategies, and targeted therapy alternatives include the central and peripheral pathways. Centrally acting agents include melanocortin receptor agonists, dopaminergic agonists and clavulanic acid (paclitaxel), while peripherally acting agents include soluble guanylate cyclase activators and Rho kinase inhibitor. Proteotherapy and gene therapy regenerate damaged erectile tissues by rejuvenating or regenerating cavernous endothelial cells and cavernous nerves or by inhibiting the fibrosis of tissues secondary to neurovascular dysfunction. This article reviews the PDE5 inhibitor therapy and androgen therapy, and introduces clinical and preclinical ED pharmacotherapy strategies, the results of which have laid a solid foundation for future clinical applications.

     

    • HTML全文
    • 参考文献(59)
  • [1] Feldman H, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates:results of the massachusetts male aging study[J]. J Urol, 1994(151): 54-61. https://www.researchgate.net/publication/14944126_Impotence_and_Its_Medical_and_Psychosocial_Correlates_Results_of_the_Massachusetts_Male_Aging_Study
    [2] Zhang X, Yang B, Li N,et al. Risk factors for erectile dysfunction in Chinese adult males[J]. J Sex Med, 2017, 14(10): 1201-8. doi: 10.1016/j.jsxm.2017.08.009
    [3] Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men[J]. J Clin Endocrinol Metab, 2007,120(92): 1245-2007.
    [4] Klein R, Klein BE, Ke LE, et al. Prevalence of self-reported erectile dysfunction in People with long-term IDDM[J]. Diabetes Care, 1996, 36(19): 135-41. http://www.oalib.com/references/12043729
    [5] Larsen SH, Wagner G, Heitmann BL. Sexual function and obesity[J]. Int J Obes, 2007,45(31): 1189-98. https://www.researchgate.net/publication/6433993_Sexual_function_and_obesity
    [6] Mcwaine DE, Procci WR. Drug-induced sexual dysfunction[J]. Med Toxicol Adverse Drug Exp, 1988, 14(3): 289-306.
    [7] Kumar RJ , Barqawi A , Crawford ED. Adverse events associated with hormonal therapy for prostate cancer[J]. Rev Urol, 2005, 7(5):37-43.
    [8] Aksam A, Yassin A , Saad F. Testosterone and erectile dysfunction[J]. J Andrology, 2008, 29(4):16-23.
    [9] Yassin A, Saad F. erectile D. Testosterone and erectile dysfunction[J]. J Androl, 2008, 29(6): 593-604. doi: 10.2164/jandrol.107.004630
    [10] Martínez-Jabaloyas JM, Gil-Salom M, Villamón-Fort R, et al. Prognostic factors for response to sildenafil in patients with erectile dysfunction[J]. Eur Urol, 2001, (40): 641-6.
    [11] Tom F, Lue M. Physiology of penile erection and pathophysiology of erectile dysfunction[C]//Campbell-walsh urology 10th, 2011: 688-720.
    [12] Morgentaler A, Goldstein I. Oral sildenafil in the treatment of erectile dysfunction[J]. J Sex Med, 2014, 11(2, SI): 117-9. http://www.jurology.com/article/S0022-5347(02)80386-X/pdf
    [13] Curran M.Tadalafil[J]. Drugs, 2003, 63(11): 2203-12.
    [14] Keating GM, Scott LJ. Vardenafil - A review of its use in erectile dysfunction[J]. Drugs, 2003, 63(23): 2673-703. doi: 10.2165/00003495-200363230-00010
    [15] Mathers MJ, Klotz T, Brandt AS, et al. Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence[J]. BJU Int, 2008, 101(9): 1129-34. doi: 10.1111/j.1464-410X.2007.07376.x
    [16] Vardi Y, Appel B, Ofer Y, et al. Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study[J]. J Urol, 2009, 182(6): 2850-5. doi: 10.1016/j.juro.2009.08.025
    [17] Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk[J]. Eur Urol, 2005, 47(2): 214-20; discussion 220-2. doi: 10.1016/j.eururo.2004.10.002
    [18] Santi D, Granata AR, Guidi AA, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial[J]. Eur J Endocrinol, 2016, 174(4): 513-22. doi: 10.1530/EJE-15-1100
    [19] Wrishko R, Sorsaburu S, Wong DA, et al. Safety, efficacy, and pharmacokinetic overview of Low-Dose daily administration of tadalafil[J]. J Sex Med, 2009, 6(7): 2039-48. doi: 10.1111/j.1743-6109.2009.01301.x
    [20] Musicki B, Burnett AL. Endothelial dysfunction in diabetic erectile dysfunction[J]. Int J Impot Res, 2007, 31(19): 129-38.
    [21] Angulo J, González-Corrochano R, Cuevas P, et al. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries[J]. J Sex Med, 2010, 7(2 Pt 1): 758-68.
    [22] Webb DJ, Gj M, Wulff M. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina[J]. J Am Coll Cardiol, 200(01): 701-5. https://www.sciencedirect.com/science/article/pii/S0735109700007051
    [23] Androgens KM. Androgens and erectile function:a case for early androgen use in postprostatectomy hypogonadal men[J]. J Sex Med, 2009, 23(5): 1743-6109.
    [24] Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction[J]. Clin Endocrinol (Oxf), 2000, 53(4): 517-22. doi: 10.1046/j.1365-2265.2000.01118.x
    [25] Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review[J]. Ther Clin Risk Manag, 2009, 5(3): 427-48.
    [26] Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists,penile erection,and sexual motivation:human studies with Melanotan II[J]. Int J Impot Res, 2000, (12): S74-9. https://www.researchgate.net/profile/Hunter_Wessells/publication/12289786_Melanocortin_receptor_agonists_penile_erection_and_sexual_motivation_Human_studies_Melanotan_II/links/54a5e9510cf257a63608d878.pdf?inViewer=0&pdfJsDownload=0&origin=publication_detail
    [27] Hellstrom W, Gittelman M, Zinner N, et al. Randomized,double-blind,placebo-controlled,at-home study to evaluate the efficacy and safety of intranasal bremelanotide in men with erectile dysfunction with and without diabetes mellitus[J]. J Sex Med, 2006, 28(3): 117-25.
    [28] Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: A randomized, double-blind, placebo controlled study[J]. J Urol , 2008, 179(3): 1066-71. doi: 10.1016/j.juro.2007.10.063
    [29] Both S.Recent developments in Psychopharmaceutical approaches to treating female sexual interest and arousal disorder[J].Curr Sex Health Rep,2017,9(4):192-9.
    [30] Cowart M, Latshaw SP, Bhatia P, et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction[J]. J Med Chem, 2004, 47(15): 3853-64. doi: 10.1021/jm030505a
    [31] Patel MV, Kolasa T, Mortell KA, et al. Discovery of 3-methyl-N-(1-oxy-3 `,4 `,5 `,6 `-tetrahydro-2 ` H-{[}2,4 `-bipyridine]-1 `-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D-4 agonist for the treatment of erectile dysfunction[J]. J Med Chem, 2006, 49(25): 7450-65. doi: 10.1021/jm060662k
    [32] Chan JS, Kim DJ, Ahn CH, et al. Clavulanic acid stimulates sexual behaviour in male rats[J]. Eur J Pharmacol, 2009(609): 69-73. https://www.sciencedirect.com/science/article/pii/S0014299909002027
    [33] Pharmaceuticals R, Inc. Efficacy study of RX-10100 to treat erectile dysfunction(ED)[EB/OL].[2009-05-05].Clinical Trials gov identifier:NCT00693056.
    [34] Clinicaltrails Gov.Clinical proof-of-concept study for the combination BAY60-4552/Vardenafil for the treatment of erectile Dysfuntion not sufficiently responsive to standard therapy with PDE5 inhibitors[EB/OL].[2014-11-04].Clinical Trails gov Identifier:NCT01168817.
    [35] Feldman H, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors:prospective results from the Massachusetts male aging study[J]. Prev Med, 2000,43(30): 328-38. https://www.sciencedirect.com/science/article/pii/S0091743500906431
    [36] Rogers RS, Graziottin T, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats[J]. Int J Impot Res, 2003, 15(1): 26-37. doi: 10.1038/sj.ijir.3900943
    [37] Dall'era JE, Meacham RB, Mills JN, et al. Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model[J]. Int J Impot Res, 2008, 20(3): 307-14. doi: 10.1038/ijir.2008.1
    [38] Gholami SS, Rogers R, Chang J, et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia[J]. J Urol, 2003, 169(5): 1577-81. https://www.sciencedirect.com/science/article/pii/S0022534705638232
    [39] Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium:deleterious effects of unregulated expression[J]. Circulation, 2000, (102): 898-901.
    [40] Chae JK, Kim I, Lim ST, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization[J]. Arterioscler Thromb Vasc Biol, 2000, 20(12): 2573-8. doi: 10.1161/01.ATV.20.12.2573
    [41] Ryu JK, Kim WJ, Koh YJ, et al. Designed angiopoietin-1 variant,COMP-angiopoietin-1,rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse[J]. Sci Rep, 2015, 12(5): 922-8.
    [42] Jin HR, Kim WJ, Song JS, et al. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse[J]. J Sex Med, 2010, 7(11): 3635-46. doi: 10.1111/j.1743-6109.2010.01925.x
    [43] Kwon MH, Ryu JK, Kim WJ, et al. Effect of intracavernous administration of angiopoietin-4 on erectile function in the Streptozotocin-Induced diabetic mouse[J]. J Sex Med, 2013, 10(12): 2912-27. doi: 10.1111/jsm.12278
    [44] Kwon MH, Tuvshintur B, Kim WJ, et al. Expression of the Apelin-APJ pathway and effects on erectile function in a mouse model of vasculogenic erectile dysfunction[J]. J Sex Med, 2013, 10(12): 2928-41. doi: 10.1111/jsm.12158
    [45] Bae JH, Shrestha KR, Park YH, et al. Comparison between subcutaneous injection of basic fibroblast growth Factor-Hydrogel and intracavernous injection of adipose-derived stem cells in a rat model of cavernous nerve injury[J]. Urology, 2014, 84(5): e1-7.
    [46] Nishimatsu H, Suzuki E, Kumano S, et al. Adrenomedullin mediates adipose tissue-derived stem cell-induced restoration of erectile function in diabetic rats[J]. J Sex Med, 2012, 9(1): 482-93.
    [47] Bennett NE, Kim JH, Wolfe DP, et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats[J]. J Urol, 2005,17(3):1820-4.
    [48] Chen KC, Minor TX, Rahman NU, et al. The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence[J]. BJU Int, 2005, (95): 1077-80.
    [49] Bakircioglu ME, Lin CS, Fan P, et al. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence[J]. J Urol, 2001, 165(05): 66301-2. https://www.sciencedirect.com/science/article/pii/S0022534705663021
    [50] Angeloni NL, Bond CW, Tang Y, et al. Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers[J]. Biomaterials, 2010, (32): 1091-101.
    [51] Choe S, Veliceasa D, Bond CW, et al. Sonic hedgehog delivery from self-assembled nanofiber hydrogels reduces the fibrotic response in models of erectile dysfunction[J]. Acta Biomater, 2016, 32(32): 89-99. https://www.sciencedirect.com/science/article/pii/S1742706116300149
    [52] Yin GN, Choi MJ, Kim WJ, et al. Inhibition of ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse[C]//Proceedings of the National Academy of Sciences of the United States of America, 2014: E2731-40.
    [53] Burnett AL, Sezen SF, Hoke A, et al. GGF2 is neuroprotective in a rat model of cavernous nerve Injury-Induced erectile dysfunction[J]. J Sex Med, 2015, 12(4): 897-905. doi: 10.1111/jsm.12834
    [54] Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury[J]. J Urol, 2004, 17(1): 495-500.
    [55] Massagué J, Chen YG. Controlling TGF-beta signaling[J]. Genes Dev, 2000, (14): 627-44.
    [56] Jin HR, Chung YG, Kim WJ, et al. A mouse model of cavernous nerve Injury-Induced erectile dysfunction: functional and morphological characterization of the corpus cavernosum[J]. J Sex Med, 2010, 7(10): 3351-64. doi: 10.1111/j.1743-6109.2010.01942.x
    [57] Li WJ, Xu MX, Gu M, et al. Losartan preserves erectile function by suppression of apoptosis and fibrosis of corpus cavernosum and corporal Veno-Occlusive dysfunction in diabetic rats[J]. Cell Physiol Biochem, 2017, 42(1): 333-45. doi: 10.1159/000477388
    [58] Song KM, Chung JS, Choi MJ, et al. Effectiveness of intracavernous delivery of adenovirus encoding Smad7 gene on erectile function in a mouse model of cavernous nerve injury[J]. J Sex Med, 2014, 11(1): 51-63. doi: 10.1111/jsm.12329
    [59] Li WJ, Wang H, Zhou J, et al. P144, a TGF-beta 1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats[J]. J Sex Med, 2013, 10(12): 2942-51. doi: 10.1111/jsm.12325
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1767
  • HTML全文浏览量:  617
  • PDF下载量:  13
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-03-02
  • 刊出日期:  2018-04-01

目录

    /

    返回文章
    返回
    • 版权所有© 2013《分子影像学杂志》编辑部 ICP备00000000号
    • 重点提示: Adobe Reader6可能造成全文显示不正常，请升级为Adobe Reader7或更高。
    • 地址: 广东省广州市广州大道北1838号 Tel: 020-61648176 E-mail: 

    本系统由 北京仁和汇智信息技术有限公司 开发  技术支持：info@rhhz.net

    x 关闭 永久关闭

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者：

    为了缩短出版时滞，促进科研成果的快速传播，我刊自2024年1月起，刊期由双月刊变更为月刊。本刊主要栏目有：基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱！

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日